BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 31818843)

  • 1. Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1).
    Wei M; Shi S; Hua J; Xu J; Yu X;
    BMJ Open; 2019 Dec; 9(12):e033452. PubMed ID: 31818843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of IRE in multi-modality treatment for oligometastatic pancreatic cancer.
    Hong Y; Rice J; Sharma D; Martin RCG
    Am J Surg; 2018 Jul; 216(1):106-110. PubMed ID: 29506753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
    Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
    BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarcinoma: protocol of a multicenter, prospective, randomized phase III control trial (CSPAC-3).
    Li J; Shi S; Liu J; Liang C; Hua J; Meng Q; Xu H; Wei M; Zhang B; Xu J; Wang W; Yu X
    Trials; 2023 Aug; 24(1):541. PubMed ID: 37592267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
    Shi HJ; Jin C; Fu DL
    World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomised controlled phase III trial.
    Liu F; Tong T; Huang D; Yuan W; Li D; Lin J; Cai S; Xu Y; Chen W; Sun Y; Zhuang J
    BMJ Open; 2019 Jan; 9(1):e017637. PubMed ID: 30700474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study.
    Roth S; Springfeld C; Diener MK; Tjaden C; Knebel P; Klaiber U; Michalski CW; Mieth M; Jäger D; Büchler MW; Hackert T
    BMJ Open; 2019 Aug; 9(8):e028696. PubMed ID: 31434770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial).
    Lau SP; van 't Land FR; van der Burg SH; Homs MYV; Lolkema MP; Aerts JGJV; van Eijck CHJ
    BMJ Open; 2022 Jun; 12(6):e060431. PubMed ID: 35710239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy.
    Crippa S; Cirocchi R; Weiss MJ; Partelli S; Reni M; Wolfgang CL; Hackert T; Falconi M
    Updates Surg; 2020 Mar; 72(1):39-45. PubMed ID: 31997233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.
    Nakano S; Kawamoto Y; Yuki S; Harada K; Miyagishima T; Sogabe S; Dazai M; Sato A; Ishiguro A; Nakamura M; Kajiura S; Takahashi Y; Tateyama M; Hatanaka K; Tsuji Y; Sasaki T; Shindo Y; Kobayashi T; Yokota I; Sakamoto N; Sakata Y; Komatsu Y
    BMJ Open; 2022 May; 12(5):e048833. PubMed ID: 35534074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
    Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
    BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection.
    Yang J; Zhang J; Lui W; Huo Y; Fu X; Yang M; Hua R; Wang L; Sun Y
    HPB (Oxford); 2020 Jan; 22(1):91-101. PubMed ID: 31262486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis.
    Tachezy M; Gebauer F; Janot M; Uhl W; Zerbi A; Montorsi M; Perinel J; Adham M; Dervenis C; Agalianos C; Malleo G; Maggino L; Stein A; Izbicki JR; Bockhorn M
    Surgery; 2016 Jul; 160(1):136-144. PubMed ID: 27048934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of natural killer cells injection combined with XELOX chemotherapy in postoperative patients with stage III colorectal cancer in China: a prospective randomised controlled clinical trial study protocol.
    Geng S; Yu X; Yu S
    BMJ Open; 2024 Mar; 14(3):e080377. PubMed ID: 38531576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
    Ai D; Chen Y; Liu Q; Zhang J; Deng J; Zhu H; Ren W; Zheng X; Li Y; Wei S; Ye J; Zhou J; Lin Q; Luo H; Cao J; Li J; Huang G; Wu K; Fan M; Yang H; Zhu Z; Zhao W; Li L; Fan J; Badakhshi H; Zhao K
    BMJ Open; 2018 Oct; 8(10):e020785. PubMed ID: 30344165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis.
    Mackay TM; van Erning FN; van der Geest LGM; de Groot JWB; Haj Mohammad N; Lemmens VE; van Laarhoven HW; Besselink MG; Wilmink JW;
    Eur J Cancer; 2019 Jan; 106():99-105. PubMed ID: 30476732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
    Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
    World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
    Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B
    World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.
    Buisman FE; Homs MYV; Grünhagen DJ; Filipe WF; Bennink RJ; Besselink MGH; Borel Rinkes IHM; Bruijnen RCG; Cercek A; D'Angelica MI; van Delden OM; Donswijk ML; van Doorn L; Doornebosch PG; Emmering J; Erdmann JI; IJzerman NS; Grootscholten C; Hagendoorn J; Kemeny NE; Kingham TP; Klompenhouwer EG; Kok NFM; Koolen S; Kuhlmann KFD; Kuiper MC; Lam MGE; Mathijssen RHJ; Moelker A; Oomen-de Hoop E; Punt CJA; Te Riele WW; Roodhart JML; Swijnenburg RJ; Prevoo W; Tanis PJ; Vermaas M; Versleijen MWJ; Veuger FP; Weterman MJ; Verhoef C; Groot Koerkamp B
    BMC Cancer; 2019 Apr; 19(1):327. PubMed ID: 30953467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.